Tessa Therapeutics Ltd: Tessa Therapeutics Announces Presentation of Autologous and Allogeneic Cell Therapy Data at 2021 ASH Annual Meeting

Presentations to feature clinical data from a Phase II CD30 CAR-T therapy study and a Phase I CD30 CAR-EBVST therapy study targeting lymphomasSINGAPORE, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Tessa Therapeutics

Related Keywords

Houston ,Texas ,United States ,Baylor College Of Medicine ,Singapore ,American ,Malcolm Brenner ,Kostenloser Wertpapierhandel ,Sairah Ahmed ,Allogeneic Vsts ,Ritika Khetawat ,American Society Of Hematology ,Tessa Scientific Co ,Tessa Therapeutics Ltd ,Us Food Drug Administration ,Md Anderson Cancer Centre ,Georgia World Congress Center ,American Society ,Annual Meeting ,Hodgkin Lymphoma ,Efficacy Profile ,T Cell Therapy ,Refractory Classical Hodgkin Lymphoma ,David Hon Quach ,Gene Therapy ,Baylor College ,Chimeric Antigen ,Virus Specifict Cells ,Scientific Co Founder ,Forward Looking ,Private Securities Litigation Reform Act ,Drug Administration ,Tessa ,Herapeutics ,Nnounces ,Presentation ,Tautologous ,Allogeneic ,Fell ,Therapy ,Data ,021 ,Nnual ,Meeting ,